A. E. Wakeling

8.4k total citations · 3 hit papers
72 papers, 6.8k citations indexed

About

A. E. Wakeling is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, A. E. Wakeling has authored 72 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Genetics, 25 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in A. E. Wakeling's work include Estrogen and related hormone effects (52 papers), HER2/EGFR in Cancer Research (20 papers) and Phytoestrogen effects and research (8 papers). A. E. Wakeling is often cited by papers focused on Estrogen and related hormone effects (52 papers), HER2/EGFR in Cancer Research (20 papers) and Phytoestrogen effects and research (8 papers). A. E. Wakeling collaborates with scholars based in United Kingdom, United States and Australia. A. E. Wakeling's co-authors include Jean Bowler, Michael Dukes, Robert I. Nicholson, C. K. Osborne, Simak Ali, Suleiman Massarweh, Rachel Schiff, Helen A. Weiss, Jianzhong Shou and M. Sikorska and has published in prestigious journals such as Journal of Clinical Oncology, The EMBO Journal and JNCI Journal of the National Cancer Institute.

In The Last Decade

A. E. Wakeling

71 papers receiving 6.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation.

1993 994 citations A. E. Wakeling et al. profile →
A potent specific pure antiestrogen with clinical potential.

1991 952 citations A. E. Wakeling, Jean Bowler et al. PubMed profile →
Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer

2004 918 citations Jianzhong Shou, Suleiman Massarweh et al. JNCI Journal of the National Cancer Institute profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
A. E. Wakeling	3.6k	3.1k	2.9k	1.0k	995	72	6.8k
Ferdinando Auricchio	2.9k 0.8×	2.7k 0.9×	1.2k 0.4×	633 0.6×	465 0.5×	93	5.1k
Ching‐yi Chang	1.8k 0.5×	2.5k 0.8×	785 0.3×	710 0.7×	1.2k 1.2×	69	4.8k
Carol A. Lange	3.3k 0.9×	6.5k 2.1×	3.4k 1.2×	609 0.6×	1.7k 1.7×	140	10.4k
Gwendal Lazennec	2.0k 0.6×	2.4k 0.8×	2.3k 0.8×	382 0.4×	839 0.8×	69	5.6k
James L. Wittliff	1.7k 0.5×	1.5k 0.5×	1.2k 0.4×	270 0.3×	881 0.9×	164	4.1k
Karen Huff	2.1k 0.6×	1.7k 0.6×	1.4k 0.5×	209 0.2×	865 0.9×	42	3.9k
Françoise Vignon	1.9k 0.5×	2.3k 0.7×	1.4k 0.5×	179 0.2×	939 0.9×	76	4.5k
Steven J. Santner	2.4k 0.7×	2.1k 0.7×	1.4k 0.5×	300 0.3×	697 0.7×	69	4.6k
Yasuo Miyoshi	1.6k 0.5×	4.6k 1.5×	3.4k 1.2×	1.0k 1.0×	2.3k 2.3×	252	9.3k

Countries citing papers authored by A. E. Wakeling

Since Specialization

Citations

This map shows the geographic impact of A. E. Wakeling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. E. Wakeling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. E. Wakeling more than expected).

Fields of papers citing papers by A. E. Wakeling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. E. Wakeling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. E. Wakeling. The network helps show where A. E. Wakeling may publish in the future.

Co-authorship network of co-authors of A. E. Wakeling

This figure shows the co-authorship network connecting the top 25 collaborators of A. E. Wakeling. A scholar is included among the top collaborators of A. E. Wakeling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. E. Wakeling. A. E. Wakeling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hutcheson, Iain R., Julia M.W. Gee, Denise Barrow, et al.. (2004). Treatment of tamoxifen-resistant MCF-7 breast cancer cells with either gefitinib ('Iressa') or trastuzumab (Herceptin((R))) generates cross-resistant phenotypes [Abstract]. Breast Cancer Research and Treatment. 2 indexed citations

Gee, Julia M.W., et al.. (2004). Characterization of ER alpha and cofactor recruitment during fulvestrant treatment and resistance in breast cancer using chromatin immunoprecipitation [Abstract]. Breast Cancer Research and Treatment. 1 indexed citations

Shou, Jianzhong, Suleiman Massarweh, C. K. Osborne, et al.. (2004). Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer. JNCI Journal of the National Cancer Institute. 96(12). 926–935. 918 indexed citations breakdown →

Lü, Chunhua, Corey Speers, Y. Zhang, et al.. (2003). Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors. JNCI Journal of the National Cancer Institute. 95(24). 1825–1833. 73 indexed citations

Morris, Charles & A. E. Wakeling. (2002). Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.. Endocrine Related Cancer. 9(4). 267–276. 53 indexed citations

Nicholson, Robert I., Iain R. Hutcheson, M. E. Harper, et al.. (2002). Modulation of Epidermal Growth Factor Receptor in Endocrine‐Resistant, Estrogen‐Receptor‐Positive Breast Cancer. Annals of the New York Academy of Sciences. 963(1). 104–115. 51 indexed citations

Nicholson, Robert I., Julia M.W. Gee, R A McClelland, et al.. (1996). Pure Antiestrogens The Most Important Advance in the Endocrine Therapy of Breast Cancer since 1896?^a. Annals of the New York Academy of Sciences. 784(1). 325–335. 11 indexed citations

McClelland, R A, et al.. (1996). Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. European Journal of Cancer. 32(3). 413–416. 41 indexed citations

Wakeling, A. E.. (1995). Tissue-specific actions of antioestrogens. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 333(1-2). 45–49. 14 indexed citations

10.

Nicholson, Robert I., Julia M.W. Gee, David L. Manning, et al.. (1995). Responses to Pure Antiestrogens (ICI 164384, ICI182780) in Estrogen‐Sensitive and‐Resistant Experimental and Clinical Breast Cancera. Annals of the New York Academy of Sciences. 761(1). 148–163. 65 indexed citations

11.

Langdon, Simon P., A. Jayne Crew, Alison Ritchie, et al.. (1994). Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. European Journal of Cancer. 30(5). 682–686. 54 indexed citations

12.

Hu, Xiangdong, M. Veroni, M. De Luise, et al.. (1993). Circumvention of tamoxifen resistance by the pure anti‐estrogen ICI 182, 780. International Journal of Cancer. 55(5). 873–876. 95 indexed citations

13.

Waterton, John C., et al.. (1993). Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging. Journal of Endocrinology. 138(2). 203–NP. 53 indexed citations

14.

Wilson, Anne, Philip J. Weatherill, Robert I. Nicholson, Peter J. Davies, & A. E. Wakeling. (1990). A comparative study of the interaction of oestradiol and the steroidal pure antioestrogen, ICI 164,384, with the molybdate-stabilized oestrogen receptor. Journal of Steroid Biochemistry. 35(3-4). 421–428. 26 indexed citations

15.

Wakeling, A. E.. (1990). Therapeutic potential of pure antioestrogens in the treatment of breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. 37(6). 771–775. 34 indexed citations

16.

Thompson, Erik W., et al.. (1989). ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness.. PubMed. 49(24 Pt 1). 6929–34. 34 indexed citations

17.

Wakeling, A. E. & Jean Bowler. (1988). Novel antioestrogens without partial agonist activity. Journal of Steroid Biochemistry. 31(4). 645–653. 171 indexed citations

18.

Wakeling, A. E. & Jean Bowler. (1988). Biology and mode of action of pure antioestrogens. Journal of Steroid Biochemistry. 30(1-6). 141–147. 114 indexed citations

19.

Furr, B.J.A. & A. E. Wakeling. (1987). Pharmacology and clinical uses of inhibitors of hormone secretion and action. 62 indexed citations

20.

Wheeler, Erica F., et al.. (1970). Abstracts of Communications. Proceedings of The Nutrition Society. 29(2). 52A–65A. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact